Ecabet sodium: a potential new agent in the management of distal colitis.
Lawrance
Ian C
IC
D045784:Abietanes / Q000627:therapeutic use*; D000208:Acute Disease; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002465:Cell Movement / Q000187:drug effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D003106:Colon / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D010766:Phosphorylation; D051381:Rats; D014945:Wound Healing / Q000187:drug effects*
D045784:Abietanes; D000897:Anti-Ulcer Agents; C061681:ecabet; D048049:Extracellular Signal-Regulated MAP Kinases